Sort
51,593 grants matching “hepatitis”
Tumor-promoting and tumor-suppressive roles of Hepatic Stellate Cell Subpopulations in NASH-HCC
$535,049Robert F. Schwabe · Columbia University Health Sciences · R01 · FY2021 · CA
Metabolomic Assessment of Estrogenic Endocrine Disruptor
$535,031Timothy R Zacharewski · Michigan State University · R01 · FY2008 · ES
Role of DGAT in Triacyglycerol Metabolism
$535,014Robert V Farese · J. David Gladstone Institutes · R01 · FY2012 · DK
Development of Controlled Release Mitochondrial Protonophore (CRMP) as a Novel Treatment for Type-2 Diabetes and Non-Alcoholic Steatohepatitis in Dysmetabolic Non-Human Primates
$534,995Gerald I Shulman · Yale University · R01 · FY2021 · DK
MICHIGAN DEPT. OF COMMUNITY HEALTH VIRAL HEPATITIS PREVENTION COORDINATION & SURE
$534,932Jim Collins · Michigan State Department Of Health And Human Services · U51 · FY2013 · PS
Modeling distinct neonatal purine metabolism to inform vaccine development
$534,907Ofer Levy · Boston Children'S Hospital · R01 · FY2014 · AI
Reducing HCV/HIV risks comparing two interventions
$534,762University Of Colorado Denver · R01 · FY2003 · DA
Novel FXR-dependent Molecular Mechanisms in the Regulation of Liver Metabolism
$534,759Peter A Edwards · University Of California Los Angeles · R01 · FY2019 · DK
Novel FXR-dependent Molecular Mechanisms in the Regulation of Liver Metabolism
$534,759Peter A Edwards · University Of California Los Angeles · R01 · FY2021 · DK
Novel FXR-dependent Molecular Mechanisms in the Regulation of Liver Metabolism
$534,759Peter A Edwards · University Of California Los Angeles · R01 · FY2020 · DK
Novel FXR-dependent Molecular Mechanisms in the Regulation of Liver Metabolism
$534,759Peter A Edwards · University Of California Los Angeles · R01 · FY2022 · DK
Dysregulation of calcium signaling in the initiation of fatty liver disease
$534,731Paula Bartlett · Rutgers Biomedical And Health Sciences · R01 · FY2024 · DK
Virally-induced tumorigenesis controlled by the microbiota
$534,676Tatyana V. Golovkina · University Of Chicago · R01 · FY2025 · CA
HIV Antiretroviral Therapy and Hepatic Injury
$534,653Kenneth E Sherman · University Of Cincinnati · R56 · FY2014 · AI
Adapt Integrated Family CBT into HIV Prevention Intervention for Pregnant Women
$534,647William W Latimer · Johns Hopkins University · R01 · FY2007 · DA
Natural History, Therapy and Pathogenesis of Chronic Viral Hepatitis B
$534,619Marc Ghany · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2016 · DK
Natural History, Therapy and Pathogenesis of Chronic Viral Hepatitis C
$534,619Marc Ghany · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2016 · DK
Training Program in Substance Use, HIV and Related Infections
$534,562Natasha Martin · University Of California, San Diego · T32 · FY2022 · DA
Determination of Molecular Mechanism of Stellate Cell-Mediated Fibrosis
$534,536Ekihiro Seki · Cedars-Sinai Medical Center · R01 · FY2025 · DK
Development of Anti-OLAM Aptamers as Novel Analgesics (Phase 2)
$534,504John G Bruno · Operational Technologies Corporation · R44 · FY2015 · GM
(PQA4) Point-of-Care Test of Exposure to Hepatocellular Carcinoma Risk by V-Chip
$534,498Lidong Qin · Methodist Hospital Research Institute · R01 · FY2013 · CA
STRUCTURE AND FUNCTION OF HUMAN TRANSLATION COMPLEXES
$534,497Jennifer A Doudna · University Of California Berkeley · P01 · FY2009 · GM
Development of a Multiscale Mechanistic Simulation of Acetaminophen Induced Liver
$534,491James Alexander Glazier · Trustees Of Indiana University · U01 · FY2014 · GM
Hyperinsulinemia and the pathogenesis of NASH
$534,426Saint Louis University · U01 · FY2004 · DK
Role of Xanthine Oxidase in Heme-induced Vascular Dysfunction
$534,408Adam Carl Straub · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · HL